SCHEMBL5908057

SCHEMBL5908057

COc1ccc2c(c1)C(C)(C)N(Cc1ccccc1)C2(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
SIGMAR1 Q99720 7/20 0.48
BCHE P06276 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
LTA4H P09960 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
DRD4 P21917 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42
OPRK1 P41145 1/20 0.42
HTR2B P41595 1/20 0.42
HTR5A P47898 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14392375 0.80 KMT2A (0.42) TDP1SIGMAR1ALDH1A1HTR1AHTR2B
SCHEMBL5970728 0.80 ELANE (0.47) SIGMAR1ALDH1A1POLBTSHRKMT2A
SCHEMBL1922770 0.80 ELANE (0.47) SIGMAR1ALDH1A1POLBTSHRKMT2A
SCHEMBL5970987 0.78 SIGMAR1 (0.44) SIGMAR1ALDH1A1HTTNR1H2NR1H3
SCHEMBL5970986 0.78 SIGMAR1 (0.44) SIGMAR1ALDH1A1HTTNR1H2NR1H3
SCHEMBL1298065 0.77 ELANE (0.42) SIGMAR1ALDH1A1POLBTSHRKMT2A
SCHEMBL13297850 0.76 ALDH1A1 (0.45) TDP1ALDH1A1HTTLTA4HMAPK1
SCHEMBL5908065 0.73 GAA (0.42) TDP1ALDH1A1POLBHTR2CTSHR
SCHEMBL20558520 0.72 SIGMAR1 (0.51) TDP1SIGMAR1HTR1ADRD4HTR2C
SCHEMBL14392728 0.72 ALDH1A1 (0.49) SIGMAR1ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060258652-A1 Beta-blockers having antioxidant and no-donor activity YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-11-16 US disclosed
WO-2004047837-A2 BETA-BLOCKERS HAVING ANTIOXIDANT AND NITRIC OXIDE-DONOR ACTIVITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258652-A1 Beta-blockers having antioxidant and no-donor activity ADRB1, ADRB2, ADRB3 TDP1 1450/4885SIGMAR1 51/4885BCHE 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.